The R28 protein of group A streptococcus (GAS) and the Rib protein of group B streptococcus (GBS) are surface molecules that elicit protective immunity to experimental infection. These proteins are members of the same family and cross-react immunologically. In spite of extensive amino acid residue identity, the cross-reactivity between R28 and Rib was found to be limited, as shown by analysis with highly purified proteins and specific antisera. Nevertheless, immunization of mice with purified R28 conferred protection against lethal infection with Rib-expressing GBS strains, and immunization with Rib conferred protection against R28-expressing GAS. Thus, R28 and Rib elicited cross-protective immunity. Characterization of many clinical GAS and GBS isolates expressing R28 or Rib, respectively, indicated that most of them expressed proteins similar to those of the reference strains. Analysis of these data suggests that cross-protection may influence the outcome of natural infections with R28-expressing GAS and Rib-expressing GBS.
The cross-reacting GAS protein, designated R28, has been found in all GAS strains of serotype M28 (hence the name R28) and is also expressed by many GAS strains of serotypes M2 and M48 [8] . Epidemiological analysis has indicated that R28-expressing strains are among the most common causes of invasive GAS disease [10] [11] [12] and that R28 may have played a pathogenetic role in the well-known epidemics of puerperal fever that occurred during earlier centuries [13, 14] . Moreover, molecular studies of the purified R28 protein and its gene have shown that R28 elicits protective immunity against R28-expressing GAS strains and that R28 promotes binding of GAS to human epithelial cells [13] . These findings focus interest on R28 as an adhesin that may act as an important virulence factor in some infections caused by GAS.
In GBS, the antigen that cross-reacts with R28 is often referred to as R [7] , but it should be noted that this designation has been used for several streptococcal antigens with different immunological specificities [7, [15] [16] [17] [18] . Little is yet known about the molecular properties of these different R antigens. However, we have purified and characterized one GBS surface protein, designated Rib, that cross-reacts with the R28 protein, and we have shown that Rib elicits protective immunity and is expressed by many GBS strains [13, [19] [20] [21] . In particular, Rib is expressed by almost all strains of serotype III, the most common serotype among GBS strains causing invasive infections [2] . Thus, R28 and Rib are 2 cross-reacting proteins, expressed by GAS and GBS, respectively, sharing the important ability to confer protective immunity. Sequence analysis has shown that R28 and Rib have extremely repetitive sequences [13, 22] and are members of the same family as the a protein of GBS [23] , a protein that also confers protective immunity [24, 25] but does not cross-react with R28 or Rib [13, 19] . A, Alignment of R28 and Rib, based on the sequences of R28 in group A streptococcus (GAS) strain AL368 [13] and of Rib in group B streptococcus (GBS) strain BM110 [22] (modified from Stålhammar-Carlemalm et al. [13] ). The processed forms of R28 and Rib have lengths of 1204 and 1176 amino acid residues, respectively. S, signal peptide; N, N-terminal nonrepeated region; R, repeat region; C, C-terminal region; PR, partial repeat. The numerals indicate the number of amino acid residues in each region or the percentage of residue identity (bold numerals) between corresponding regions. Within each protein, the 79-residue repeats are identical. The N-terminal region of R28 includes a 195-residue region (shaded), which does not fit into the alignment shown here (see text). B, Inhibition tests with highly purified proteins and specific antisera. The binding of rabbit anti-R28 to R28 was inhibited by the addition of increasing amounts of R28, Rib or b (B, left panel). Alternatively, the binding of anti-Rib to Rib was inhibited with the same proteins (B, right panel) C, Inhibition tests with whole bacteria. As shown in the left panel, the binding of mouse anti-R28 to immobilized R28 was inhibited by the addition of increasing amounts of washed bacteria. Strains used were the R28-expressing GAS strain AL368, the Rib-expressing GBS strain BM110, and the GAS strain AW43, which does not express R28 or Rib (control). As shown in the right panel, the binding of mouse anti-Rib to Rib was inhibited with the same bacteria. Each experiment was performed at least twice, with similar results.
The R28 and Rib proteins show extensive residue identity in the repeat regions, which may explain the cross-reactivity of these 2 proteins (figure 1A). In contrast, the sequences show major differences in the nonrepeated N-terminal regions. Analysis of data reported here shows that the immunological crossreactivity between R28 and Rib is surprisingly limited but is sufficient to elicit cross-protective immunity in experimental infections. Thus, R28 and Rib are surface proteins that elicit cross-protection between 2 bacterial species causing different diseases.
Materials and Methods
Bacterial strains and media. The R28-expressing GAS strains AL368 and Griffith have been described elsewhere [7, 13] . AW43 is an M60 GAS strain lacking R28 [13] . A collection of 14 R28-expressing GAS strains has been described elsewhere [13] . The GBS type III strains BM110 and BS30 express Rib [19, 22] . The type Ib strain SB35, its mouse virulent derivative SB35sed1, and the type II strain BS29 express the a and b proteins [19, 20] . We obtained the GBS type II strain 1954/92 from Dr. R. Facklam (Centers for Disease Control and Prevention, Atlanta), and the type II strain 118/158 was obtained from Dr. J. Jelinkova (National Institute of Public Health, Prague). The GBS type III prototype strain D136C [15, 26] was obtained from Dr. J. Michel (Channing Laboratory, Boston). The GBS type V strain 2471 was from Dr. G. Orefici (Istituto Superiore di Sanita, Rome). Additional Rib-expressing GBS strains of types II and III were available in our collections. Streptococci were grown in Todd-Hewitt broth (Oxoid, Basingstoke, UK) at 37ºC, without shaking.
Construction of an R28-negative mutant of GAS strain Griffith. The procedure was similar to that used to isolate an R28-negative mutant of GAS strain AL368 [13] . In the mutant, the central repeat region of the spr28 gene, which encodes R28, has been replaced with a kanamycin resistance cassette. The absence of the spr28 gene in the mutant was verified by polymerase chain reaction analysis. The mutant lacked expression of R28, as shown by analysis of whole bacteria and of bacterial extracts [13] . The effects of the mutation in the spr28 gene of strain Griffith cannot be due to a polar effect, since the gene located downstream of spr28 is transcribed in the opposite direction (data not shown), a situation similar to that observed in strain AL368 [13] .
Purified proteins and antisera. The R28 protein was purified from GAS strain AL368 as described elsewhere [13] . The GBS proteins Rib and b were purified from strains BM110 and SB35, as described elsewhere [19, 20] . These highly purified protein preparations were homogeneous and did not contain detectable amounts of contaminating proteins or polysaccharides [20] . Antisera were raised in rabbits and mice, as described elsewhere [19, 20] , by use of complete Freund's adjuvant (CFA).
Inhibition tests for analysis of cross-reactivity. Microtiter plates (Falcon 3912; Becton Dickinson, Oxnard, CA) were coated with purified protein (R28 or Rib) by incubation for 16 h with 100 mL of a solution of protein (500 ng/mL) in PBS. The wells were blocked by incubation for ∼2 h with 150 mL veronal-buffered saline (10 mM veronal buffer, 0.15 M NaCl, pH 7.4) supplemented with 0.25% gelatin and 0.25% Tween-20 and washed 3 times with PBS with 0.02% sodium azide and 0.05% Tween-20 (PBSAT). The binding of antibodies to the immobilized protein was inhibited with purified proteins or with whole bacteria. For inhibition tests with purified proteins, aliquots of antiserum in PBSAT (100 mL) were mixed with different amounts of protein and preincubated for 30 min, then added to the coated wells. The antisera were used at a final dilution corresponding to ∼80% of maximal binding. After incubation for 3 h, the wells were washed 3 times with PBSAT, and bound antibodies were detected by the addition of 125 I-labeled protein A or protein G (∼15,000 cpm in 100 mL of PBSAT for each well). Protein A was used for mouse antibodies and protein G for rabbit antibodies. After incubation for 2 h and washing 3 times with PBSAT, the radioactivity of each well was determined. Nonspecific binding (!1%) was determined in wells coated with PBS alone and was subtracted. All incubations were performed at room temperature. In the absence of inhibitor, ∼50% of the radiolabeled protein A or G was bound. Inhibition was calculated as a percentage of this binding. For inhibition tests with whole bacteria, washed suspensions of bacteria in PBSAT were used instead of purified proteins. Since protein A and protein G were used in the tests described here, these tests measured cross-reactive antibodies of the IgG isotype [27] . Protein A may also detect some IgM molecules [28] , but the mouse sera used here did not contain detectable IgM against the proteins studied, as measured by ELISA (data not shown).
Protection of mice by active and passive immunization. For active immunization with purified R28, mice (male C3H/HeN; ages, 8-10 weeks) were vaccinated subcutaneously with 25 mg of protein in CFA and boosted 4 weeks later with the same amount in IFA. Control mice received bovine serum albumin; we used the same adjuvants. Two weeks after the booster, the mice were challenged by intraperitoneal (ip) injection with an ∼90% lethal dose of logphase GBS (10 6 -10 7 colony-forming units [cfu], depending on the strain) [19, 20] . Deaths were recorded daily for 7-10 days. Active immunization with purified Rib was performed in the same way, but Rib was administered in PBS, since recent data have shown that this protein is also immunogenic without adjuvant [21] . Control mice received PBS. These mice were challenged with 5 ϫ 10 4 cfu of GAS strain Griffith.
For passive immunization, mice were injected ip with 100 mL of rabbit antiserum (diluted in PBS to a volume of 0.5 mL) and challenged 4 h later by ip injection of an ∼90% lethal dose of bacteria. GAS strain Griffith and an R28-negative mutant of this strain were used in these experiments, because this strain is more virulent for mice than a GAS strain studied previously [13] . The 2-tailed Fisher's exact test was used for statistical analysis of all protection tests with mice.
Other methods. Proteins were radiolabeled with carrier-free 125 I (Amersham, Amersham, UK) by the chloramine T method. Determination of specific antibodies by ELISA was performed as described elsewhere [20] . Analysis of bacteria for surface expression of proteins was performed as described elsewhere [13] .
Results
The R28 and Rib proteins show limited immunological crossreactivity. Features of R28 and Rib relevant to this study are summarized in figure 1A . The residue identity is 59% in the most N-terminal parts of the processed forms of the proteins, increasing to 95% in the repeat regions and in the most Cterminal regions. However, the nonrepeated region of R28 includes a region (shaded in figure 1A ) that is largely unique to this protein. The first part of this region shows 36% similarity to the repeat regions of R28 and Rib, whereas the second and longer part shows 36% identity to a region in the GBS protein b, which is unrelated to R28 and Rib [29, 30] .
The cross-reactivity between R28 and Rib was analyzed in inhibition experiments, in which the binding of antibodies to A, Results of experiments in which 1 group of mice was immunized with pure R28 and 1 group (the control group) was immunized with bovine serum albumin. Immunized mice were challenged intraperitoneally with an ∼90% lethal dose of the group B streptococcus (GBS) strain designated in the upper right-hand corner of each graph. For each of these GBS strains, the following information is given: relevant surface protein or proteins, capsular serotype, and name of the strain. After challenge with the GBS strain, deaths were recorded daily for 7 d. The final ratios (number of surviving mice:number of mice challenged) are indicated. Differences in survival in the 2 groups were used to calculate P values by Fisher's exact test. B, Results of an experiment in which mice were immunized with pure Rib or with PBS (control) and challenged with the R28-expressing group A streptococcus (GAS) strain Griffith.
an immobilized protein was inhibited by the addition of highly purified proteins (figure 1B). The binding of anti-R28 to R28 was completely inhibited by the addition of R28, but addition of Rib did not cause 1∼40% inhibition, even at the highest concentration tested ( figure 1B, left panel) . As expected, addition of the b protein did not cause any inhibition. In reciprocal experiments, the binding of anti-Rib to Rib was inhibited with the different proteins ( figure 1B, right panel) . The difference in inhibitory capacity between R28 and Rib was even more pronounced in this case. Indeed, R28 caused maximal inhibition, ∼30%, only when present at very high concentrations. These results were not due to unusual properties of the rabbit antisera used, because similar results were obtained with mouse antisera (data not shown). Analysis of these data demonstrates that purified R28 and Rib show only limited cross-reactivity.
Tests were also performed to analyze the cross-reactivity between R28 and Rib expressed on the bacterial surface ( figure  1C ). Washed suspensions of whole bacteria were added to a test system similar to that described above. However, mouse, rather than rabbit, antisera were used, to avoid interactions with GAS surface proteins (M proteins) that bind rabbit IgGFc [31, 32] . The binding of anti-R28 to R28 was completely inhibited by R28-expressing GAS bacteria but was inhibited only poorly by Rib-expressing GBS ( figure 1C, left panel) . Similar results were obtained when the binding of anti-Rib to Rib was inhibited with whole bacteria ( figure 1C, right panel) . These data cannot be explained by quantitative differences in surface expression of Rib and R28 but indicate that the 2 proteins show very limited cross-reactivity when they are expressed on the bacterial surface, in agreement with the results obtained with purified proteins (figure 1B). Indeed, comparison of the data obtained with pure proteins and with whole bacteria suggests that the cross-reactivity between R28 and Rib may be even more limited when the proteins are expressed on the bacterial cell surface, possibly because the repeat regions in surfaceanchored proteins are less accessible to antibodies than are the wall-distal N-terminal regions.
Antibodies to R28 or Rib confer cross-protection. A mouse model was used to analyze whether the limited cross-reactivity between R28 and Rib is sufficient to cause cross-protection. Mice were immunized with highly purified R28 (or with bovine serum albumin as a control) and were tested for immunity to lethal GBS infection (figure 2A). The GBS strains studied represented 4 different capsular serotypes. Immunization with R28 protected against 2 Rib-expressing GBS strains of type III (including the reference strain BM110 that was used to sequence Rib) and against 2 Rib-expressing GBS strains of type II. All 4 of these GBS strains express Rib proteins that appear to be immunologically identical (see below). In addition, immunization with R28 protected against a type V strain expressing a Rib-like protein (see below). In contrast, immunization with R28 did not confer significant protection against infection with 2 GBS strains (of types Ib and II), expressing the a and b proteins. Thus, R28 elicited protective immunity against GBS strains expressing the cross-reacting Rib protein, but not against strains expressing protein a, which is a member of the same Figure 3 . Anti-Rib antibodies protect against infection with an R28-expressing group A streptococcus (GAS) strain (A) but not against infection with an R28-negative mutant (B) of that strain. A, Results of an experiment in which mice were injected intraperitoneally (ip) with rabbit antiserum raised against highly purified Rib or with preimmune serum. Four hours later, the mice were challenged ip with ∼90% lethal dose of GAS strain Griffith, which expresses R28. Deaths were recorded daily, as indicated. Fisher's exact test was used for statistical analysis. B, Results of an experiment in which mice were treated as in A but were challenged with an R28-negative mutant of strain Griffith.
family as R28 and Rib but does not cross-react with these proteins.
Immunization with pure Rib also conferred cross-protection (figure 2B). The strain used for challenge in this experiment was not the reference R28 strain, which was poorly mouse virulent (like most clinical GAS isolates), but the mouse-virulent and R28-expressing GAS strain Griffith. Polymerase chain reaction analysis and immunological characterization indicated that the R28 protein expressed by this strain is identical to the R28 protein of the reference strain (data not shown). In this analysis of cross-protection after immunization with Rib, the mice were immunized without adjuvant, because recent experiments had indicated that Rib is also highly immunogenic under these conditions [21] .
The immunization experiments described above strongly suggested that antibodies to R28 and Rib confer cross-protection because of the immunological cross-reactivity between these 2 proteins. However, the possibility could not be formally excluded that the cross-protection was due to some other crossreacting surface component. To analyze this hypothesis, we performed protection experiments with the R28-expressing GAS strain Griffith and an R28-negative mutant of this strain. This experiment was performed on the basis of our previous finding that an R28-negative mutant is still virulent in the ip infection model, most likely because the function of R28 is to act as an adhesin at the early stages of an infection, stages that are bypassed in this model [13] . However, R28 on the bacterial surface can act as a target for protective antibodies also in this ip infection model [13] . This situation made it possible to analyze whether the cross-protection observed with anti-Rib antibodies was due to cross-reactivity with a surface component different from R28. If this were the case, anti-Rib antibodies would be expected to confer protection against the R28-negative mutant as well. A passive immunization model was used to study this problem ( figure 3 ). As expected, anti-Rib serum, but not preimmune serum, efficiently protected against lethal infection with the R28-expressing strain ( figure 3A) . In contrast, anti-Rib serum did not protect against infection with the R28-negative mutant (figure 3B), indicating that the cross-protection described above was indeed due to immunological cross-reactivity between R28 and Rib.
Comparison of R28 and Rib proteins expressed by different isolates.
To analyze whether R28 and Rib proteins expressed by different clinical isolates have properties similar to those of the reference proteins, inhibition tests were performed with whole bacteria. Strains of GAS classified as R28-positive (reacting with anti-R28 serum) were analyzed in inhibition tests with R28 purified from the reference strain and antiserum against this protein ( figure 4A ). Controls showed that the reference strain (AL368) caused complete inhibition, whereas a GAS strain lacking R28 did not inhibit. Among 14 R28-expressing strains analyzed, all caused complete inhibition, indicating that they express R28 proteins that are immunologically similar, if not identical, to R28 of the reference strain. Data for 3 of these strains are shown in figure 4A . For unknown reasons, 2 of 14 R28-expressing strains were less efficient inhibitors than strain AL368, but complete inhibition also was obtained with these strains. Data for 1 of these 2 strains (35-96) are included in figure 4A .
Different GBS strains classified as Rib-positive (reacting with anti-Rib serum) were also analyzed in inhibition tests ( figure  4B ). As expected, complete inhibition was observed with the reference strain BM110. Eleven strains of the clinically important type III and 5 strains of type II also caused complete inhibition, indicating that they express Rib proteins that are immunologically similar, if not identical, to Rib of the reference strain. Data for 3 of these strains are included in figure 4B . However, other data indicated that some GBS strains express a protein that is not immunologically identical to Rib. In particular, some GBS strains of serotype V express a Rib-like protein [33] , and a strain expressing this protein caused only partial inhibition ( figure 4C ). Among GBS type III strains, an atypical result was obtained with D136C, a reference strain for GBS type III [15, 26] . This strain expresses a protein that is recognized by anti-R28 serum [34] , suggesting that D136C might express Rib, like most other GBS type III strains. However, the protein expressed by D136C is not Rib, because D136C bacteria completely lacked activity in the inhibition test with anti-Rib serum ( figure 4C) . Indeed, preliminary analysis indicated that the D136C protein is neither Rib nor R28 (data not shown). In spite of the properties of this strain, analysis of our data indicates that most GBS strains of the clinically important type III express proteins that are very similar to the Rib protein of the reference strain BM110. 
Discussion
The importance of infections caused by GAS and GBS, and the lack of human vaccines, makes it essential to characterize antigens that elicit protective immunity to these pathogens. Extensive studies have therefore been devoted to the M protein of GAS and the polysaccharide capsule of GBS, both of which are major virulence factors that elicit protective immunity to experimental infection [2, 3, 5] . However, antigenic variation and other problems make it uncertain whether any of these antigens will be suitable for vaccine development [3, 20] . Thus, it is important to characterize other surface antigens that elicit protective immunity to infections caused by GAS or GBS. In GAS, such surface antigens include the R28 protein [13] , the SfbI protein [35] , and the Spa protein [36] . In GBS, the 3 surface proteins Rib, a, and b elicit protective immunity against infection with strains expressing the corresponding antigen [19-21, 24, 25] .
In this study, we compared 2 of the protective antigens referred to above, the cross-reacting R28 and Rib proteins that are expressed by GAS and GBS, respectively. The most important result of our work is the demonstration that R28 and Rib elicit protective immunity not only against strains expressing the homologous protein but also against strains expressing the heterologous protein, although the immunological crossreactivity between R28 and Rib is surprisingly limited.
In a sequence alignment, the R28 and Rib proteins appear to be very similar because of the almost complete residue identity in the repeat regions ( figure 1A) . However, all repeats within each protein are identical, implying that only a single repeat from each protein should be considered in an immunological comparison of the 2 proteins. Viewed this way, R28 and Rib can be subdivided into 3 regions: an N-terminal region of 173-174 residues showing 59% identity, a 195-residue region that is largely unique to R28, and a 79-residue (repeat) region showing 95% identity. This comparison makes it less surprising that R28 and Rib showed only limited immunological crossreactivity. Indeed, previous studies of the GBS protein a have shown that this protein does not cross-react with R28 or Rib, although the residue identity between a and Rib/R28 is у61% in the N-terminal region and is 44%-47% in the repeat region [13, 22] . Although the cross-reactivity between R28 and Rib is limited, it was sufficient to allow cross-protection in a mouse model.
Studies of many different streptococcal strains indicated that all GAS strains classified as R28-positive express immunologically identical R28 proteins and that most GBS strains classified as Rib-positive express immunologically identical Rib proteins. Therefore, the results on cross-protection, which were obtained with proteins purified from reference strains, are most likely valid also for proteins expressed by other strains. If we assume that the proteins are immunogenic also during infections in humans, analysis of these data suggests that infection with an R28-expressing GAS strain may elicit immunity against subsequent infection with any Rib-expressing GBS strain and vice versa. Moreover, it seems possible that inclusion of protein Rib in a human GBS vaccine [21] may confer protection not only against Rib-expressing GBS strains but also against R28-expressing GAS strains. Although it is not yet known whether R28 and Rib are immunogenic during infections in humans, it seems likely that this is the case, since R28 and Rib are highly immunogenic in mice and are equally immunogenic, whether they are administered in PBS or in CFA [21; authors' unpublished data).
In another example of cross-protection due to related antigens expressed by different bacterial species, it was reported that antibodies to Streptococcus pneumoniae type 14 protected suckling rats against infection with GBS type III [37] . Although the cross-protective antigen was not identified, it was most likely the polysaccharide capsule, which is structurally similar in S. pneumoniae type 14 and GBS type III [38] . Taken together, the available data therefore suggest that protective immunity against experimental infection with GBS type III may be elicited not only by immunization with GBS antigens [21, 39] but also by immunization with the capsule of S. pneumoniae type 14 or with the R28 protein of GAS. If such cross-protection between pathogens of different species also occurs in human infections, it may be of general importance for the sensitivity to bacterial infections. Indeed, it has recently been suggested that infants may acquire immunity to Haemophilus influenzae type b through cross-reacting antibodies elicited by other bacterial antigens [40] . Moreover, there is evidence that heterologous immunity may contribute to the resistance to viral infections [41] . Thus, data are now accumulating that the history of infections in an individual may influence susceptibility to subsequent infections with other pathogens.
